Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Interesting

<< Previous

Bullboard Posts

Next >>

Comment by StockingUp21on Jun 26, 2022 10:22am

102 Views

Post# 34782991

RE:RE:RE:RE:Interesting

9 years later how is the progress

MrMugsy wrote:

themagicbox wrote: Indomethacin, huh. Usually thats prescribed for a gout flare up.

Interesting ... if we look back at the 2013 preliminary prespectus, we see ...

1. 346 - Naproxen identified for OA, RA, Ankylosing Spondylitis, dysmenorrhea, dental pain and general pain.

2. 344 - Indomethacin, for acute gout

3. Other candidates

---------------------------------

Market size for 344 was identified at $500M